High clinical, economic burden with hemophilia A or B in France
Healthcare costs, particularly related to disease-specific medications, are especially high for people with hemophilia A or hemophilia B…
Articles by Andrea Lobo, PhD
NICE recommends Altuvoct as NHS treatment option for hemophilia A
The U.K.’s National Institute for Health and Care Excellence (NICE) has recommended Altuvoct (efanesoctocog alfa) be available through the…
Altuvoct approved in UK as treatment for hemophilia A patients
The U.K. Medicines and Healthcare products Regulatory Agency (MHRA) has approved efanesoctocog alfa — to be sold under the…
Be Bio raises $92M to advance hemophilia B treatment BE-101
Be Biopharma has raised $92 million in series C financing to support the first-in-human Phase 1/2 trial of BE-101,…
Man’s joint damage eased by gene therapy, robotic hip replacement
Combining gene therapy with minimally invasive, robot-assisted hip replacement surgery safely and effectively treated severe joint damage for a 27-year-old…
Liver cancer seen as common risk for men with hemophilia and HIV
Men with hemophilia and infected with the human immunodeficiency virus (HIV) are at a high risk of developing certain…
IND-enabling studies for hemophilia A gene-editing therapy to advance
Metagenomi, which is developing MGX-001, a gene-editing therapy for hemophilia A, is preparing to initiate investigational new drug…
Centessa discontinues development of SerpinPC for hemophilia
Centessa Pharmaceuticals is discontinuing the clinical development of SerpinPC, its experimental under-the-skin therapy for people with hemophilia A…
Hemophilia patients more likely to be infected with SENV: Study
People with hemophilia are more likely to be infected with the SEN virus (SENV), which is associated with blood…
Reimbursement urged in Spain for Hemgenix hemophilia B treatment
The Spanish Interministerial Commission on the Pricing of Medicines, known as CIPM, has issued a positive recommendation for national reimbursement…